165 related articles for article (PubMed ID: 6174459)
1. Lysis of fresh human B-lymphocyte-derived leukemia cells by interferon-activated natural killer (NK) cells.
Pattengale PK; Gidlund M; Nilsson K; Sundström C; Sällström J; Simonsson B; Wigzell H
Int J Cancer; 1982 Jan; 29(1):1-7. PubMed ID: 6174459
[TBL] [Abstract][Full Text] [Related]
2. Lysis of human B-lymphocyte-derived lymphoma/leukemia cells of established cell lines by interferon-activated natural killer (NK) cells.
Pattengale PK; Gidlund M; Nilsson K; Sundström C; Orn A; Wigzell H
Int J Cancer; 1981 Oct; 28(4):459-68. PubMed ID: 6171529
[TBL] [Abstract][Full Text] [Related]
3. Lysis of fresh leukemic blasts by interferon-activated human natural killer cells.
Pattengale PK; Sundstrom C; Yu AL; Levine A
Nat Immun Cell Growth Regul; 1983-1984; 3(4):165-80. PubMed ID: 6597341
[TBL] [Abstract][Full Text] [Related]
4. Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia.
Ziegler HW; Kay NE; Zarling JM
Int J Cancer; 1981 Mar; 27(3):321-7. PubMed ID: 6169660
[TBL] [Abstract][Full Text] [Related]
5. Discrepancy between phenotypic and functional features of natural killer T-lymphocytes in B-cell chronic lymphocytic leukaemia.
Foa R; Lauria F; Lusso P; Giubellino MC; Fierro MT; Ferrando ML; Raspadori D; Matera L
Br J Haematol; 1984 Nov; 58(3):509-16. PubMed ID: 6333890
[TBL] [Abstract][Full Text] [Related]
6. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
7. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy.
Guven H; Gilljam M; Chambers BJ; Ljunggren HG; Christensson B; Kimby E; Dilber MS
Leukemia; 2003 Oct; 17(10):1973-80. PubMed ID: 14513047
[TBL] [Abstract][Full Text] [Related]
8. Restoration of impaired natural killer cell activity of B-chronic lymphocytic leukemia patients by recombinant interleukin-2.
Kay NE; Zarling J
Am J Hematol; 1987 Feb; 24(2):161-7. PubMed ID: 3028132
[TBL] [Abstract][Full Text] [Related]
9. Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells.
Mizutani Y; Bonavida B; Nio Y; Yoshida O
Cancer; 1993 Feb; 71(4):1313-21. PubMed ID: 7679609
[TBL] [Abstract][Full Text] [Related]
10. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA
J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774
[TBL] [Abstract][Full Text] [Related]
11. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
[TBL] [Abstract][Full Text] [Related]
12. Augmentation of human natural killer cell activity by cyclophosphamide in vitro.
Sharma B; Vaziri ND
Cancer Res; 1984 Aug; 44(8):3258-61. PubMed ID: 6589041
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
[TBL] [Abstract][Full Text] [Related]
14. The relationship between multi-drug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in human leukemic cell lines.
Treichel RS; Olken S
Int J Cancer; 1992 Jan; 50(2):305-10. PubMed ID: 1370437
[TBL] [Abstract][Full Text] [Related]
15. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
16. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of cell-mediated cytotoxicity at the single cell level. VI. Direct assessment of the cytotoxic potential of human peripheral blood non-lytic effector-target cell conjugates.
Bonavida B; Lebow LT; Bradley TP
J Immunol; 1984 Feb; 132(2):594-8. PubMed ID: 6606675
[TBL] [Abstract][Full Text] [Related]
18. The use of VEP13 monoclonal antibody for definition of natural killer cells: spontaneous killer cells directed against fresh human leukaemia cells carry the VEP13 antigen.
Ziegler-Heitbrock HW; Fütterer A; Rumpold H; Kraft D; Munker R; Riethmüller G
Clin Exp Immunol; 1984 Nov; 58(2):470-7. PubMed ID: 6333947
[TBL] [Abstract][Full Text] [Related]
19. IFN-gamma treatment of K562 cells inhibits natural killer cell triggering and decreases the susceptibility to lysis by cytoplasmic granules from large granular lymphocytes.
Grönberg A; Ferm MT; Ng J; Reynolds CW; Ortaldo JR
J Immunol; 1988 Jun; 140(12):4397-402. PubMed ID: 3131433
[TBL] [Abstract][Full Text] [Related]
20. Chemiluminescence response of human natural killer cells. I. The relationship between target cell binding, chemiluminescence, and cytolysis.
Helfand SL; Werkmeister J; Roder JC
J Exp Med; 1982 Aug; 156(2):492-505. PubMed ID: 6178787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
